[大发心律失常和局部提摩洛尔:突出需要药物调和]
Aristide Prodolliet1, Laetitia Bouvard2, Amandine Berner2
1Service des urgences, Hôpital de La Tour, 1217 Meyrin/Genève.
Revue medicale suisse
|September 18, 2025
概括
像提摩洛尔这样的局部眼科β-阻塞剂可以在老年患者中引起严重的全身副作用,例如心率减慢. 总是检查所有的药物,包括眼药,以防止不良药物事件.
科学领域:
- 眼科医生 眼科 眼科
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
背景情况:
- 眼科β-阻断剂,如蒂莫洛尔,经常用于青光眼.
- 这些药物可以通过眼睛和鼻子途径系统吸收.
- 显著的系统吸收可以导致心血管不良事件,特别是在脆弱人群中.
研究的目的:
- 在老年患者中报告症状勃节律失常的病例,该病例归因于局部提摩洛尔.
- 强调在药物不良事件调查中考虑非口服药物的重要性.
主要方法:
- 一个94岁的女性患者的病例报告.
- 详细的临床病史,药物审查和症状评估.
- 在改变药物后观察症状的消失.
主要成果:
- 患者出现了症状勃节律失常,包括鼻暂停和心房动,心室反应缓慢.
- 这些症状暂时与局部提摩洛尔眼滴的使用有关.
- 停止提摩洛尔治疗并替换为非β-阻断剂导致症状完全消失.
结论:
- 局部提摩洛尔可以在老年患者中引起临床显著的全身勃拉迪亚心律失常.
- 综合药物调和,包括局部和非口服配方,对于预防不良药物事件至关重要.
- 对所有药物配方的系统评估对于评估老年多病症患者的心血管影响至关重要.
相关概念视频
Dysrhythmias IV: Characteristics of Bradyarrhythmias
500
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
500
Decreased pulse rate
843
Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
843
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Dysrhythmias VI: Management of Dysrhythmias
433
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
433
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Cardiopulmonary Resuscitation IV: Pharmacological Management
675
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
675


